Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Meet the Experts

The team at Richmond Pharmacology have extensive knowledge and expertise in every area of Early Phase clinical trials. Our founding Directors are clinical pharmacologists and lead a dedicated, competent, and motivated team of experienced managers and personnel.

Our employees regularly receive high quality training. The rigorous approval process we have in place ensures the highest standard of conduct for studies.

Richmond Pharmacology's reputation extends beyond the boundaries of our London Bridge Unit. Due to our standing within the industry, we have developed partnerships with eminent Professors, Surgeons and Doctors who all contribute to the conduct of our clinical trials.

Book our experts as speakers at your event

We regularly present at international clinical events. If you would like one of our experts to speak at your event, please support your enquiry below.

Your enquiry has been sent. A member of our team will be in touch shortly.
Looks like we're having trouble

Key Scientific and Operational Personnel

Dr Jorg Taubel MD, FFPM, FESC

Dr Jorg Taubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001.

Read biography

Keith Berelowitz MSC
Director of Operations

A scientist by training, Keith has worked in clinical research (academic and commercial) for over 22 years.

Read biography

Dr Ulrike Lorch MD, FRCA, FFPM
Medical Director

Dr Ulrike Lorch is a Co-Founder and Medical Director of Richmond Pharmacology. She holds Specialist Accreditation in Pharmaceutical Medicine.

Read biography

Dilshat Djumanov MPhil, PhD
Director of Data Science

Dilshat has an in depth knowledge of data management and data analysis for adaptive clinical trials and QTc studies.

Read biography

Emma Akuffo BSC, PhD
Director of Study Management

Emma oversees the Study Management, Advanced Research Science and Quality Assurance teams at Richmond Pharmacology.

Read biography

Scientific Advisory Board

Professor Anand
Professor of Neurology

Professor Praveen Anand studied medicine at Cambridge University.

Read biography

Professor Camm
Professor of Cardiology

Professor Camm studied medicine at Guy's Hospital Medical School, London.

Read biography

Professor Kaski
Professor of Cardiology

In 2001, Professor Kaski was awarded the degree of Doctor of Science (DSc) by the University of London.

Read biography

Professor McLean
Professor Emeritus of Toxicology

Professor Andre McLean studied medicine at Oxford and University College Hospital.

Read biography

Professor Oliveira
Professor of Renal Medicine

Professor David Oliveira studied medicine at Cambridge University as well as Westminster Hospital Medical School where he qualified in 1979.

Read biography

External Experts

Professor Dalgliesh
Professor of Oncology

Professor Angus Dalgliesh graduated from University College Hospital, London and obtained an MBBS with an intercalated BSc Hons in Anatomy under Professor J. J. Young, FRS.

Read biography

Professor Axford
Professor of Rheumatology

Professor John Axford studied medicine at University College, London in 1989.

Read biography

Dr Von Oertzen
Consultant Neurologist and Epileptologist

Dr. von Oertzen studied medicine at Rheinische-Friedrich-Wilhelm University, Germany .

Read biography

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

What 20 years of clinical research has taught us about our industry and the future of drug development

June 9, 2021
As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes.
Read more

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more